The investment will support the company’s transition into clinical development of its immunomodulatory treatment for atopic dermatitis, they state. The EUR 4.3 million raised will enable the completion of toxicology studies, GMP production, and initiation of the company’s first Phase Ib clinical trial in patients with atopic dermatitis.

“This capital injection enables us to take the decisive step into clinical development and move closer to a future where patients have access to more durable and effective treatment. The strong support from Sciety and their investor network gives us both the momentum and the means to accelerate our development,” says Leo Holmgren, CEO of TIRmed Pharma.

Based on an oligonucleotide

TIRmed Pharma is developing a novel treatment based on an oligonucleotide applied directly to the skin, acting locally by modulating the immune system at the site of disease. This targeted, immunomodulatory mechanism of action helps reduce systemic exposure and thereby minimizes the risk of side effects, describes the company.

Related article

A new national technology platform for oligonucleotide drugs

The Swedish center, called the OligoNova Hub, will be located at the University of Gothenburg. The Wallenberg Centre for Molecular and Translational Medicine has been awarded SEK 54 million by the Knut and Alice Wallenberg Foundation, and SEK 48 million from SciLifeLab and the University of Gothenburg, to create the national technology platform. It will […]

In preclinical studies, the treatment has shown promising results, including sustained
symptom relief for up to 15 months after just five applications over two weeks.